Literature DB >> 10389971

Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours.

C Ghimenti1, P Tannergård, S Wahlberg, T Liu, P G Giulianotti, F Mosca, G Fornaciari, G Bevilacqua, A Lindblom, M A Caligo.   

Abstract

Genomic instability has been proposed as a new mechanism of carcinogenesis involved in hereditary non-polyposis colorectal cancer (HNPCC) and in a large number of sporadic cancers like pancreatic and colon tumours. Mutations in human mismatch repair genes have been found in HNPCC patients, but their involvement in sporadic cancer has not been clarified yet. In this study we screened 21 pancreatic and 23 colorectal sporadic cancers for microsatellite instability by ten and six different microsatellite markers respectively. Microsatellite alterations were observed at one or more loci in 66.6% (14/21) of pancreatic cancers and in 26% (6/23) colon tumours, but all the pancreatic and half of the colon samples showed a low rate of microsatellite instability. All the unstable samples were further analysed for mutations in the hMLH1 and hMSH2 genes and for hypermethylation of the hMLH1 promoter region. Alterations in the hMLH1 gene were found only in colorectal tumours with a large presence of microsatellite instability. None of the pancreatic tumours showed any alteration in the two genes analysed. Our results demonstrate that microsatellite instability is unlikely to play a role in the tumorigenesis of sporadic pancreatic cancers and confirm the presence of mismatch repair gene alterations only in sporadic colon tumours with a highly unstable phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389971      PMCID: PMC2363009          DOI: 10.1038/sj.bjc.6690314

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype.

Authors:  N C Nicolaides; S J Littman; P Modrich; K W Kinzler; B Vogelstein
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

Review 2.  Mutation detection by denaturing gradient gel electrophoresis (DGGE).

Authors:  R Fodde; M Losekoot
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

Review 3.  Microsatellite instability: marker of a mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  1994-10-01       Impact factor: 12.701

4.  DGGE polymorphism in intron 10 of MSH2, the HNPCC gene.

Authors:  J Wijnen; R Fodde; P M Khan
Journal:  Hum Mol Genet       Date:  1994-12       Impact factor: 6.150

5.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

Authors:  H Kim; J Jen; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

6.  A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype.

Authors:  G Aquilina; P Hess; P Branch; C MacGeoch; I Casciano; P Karran; M Bignami
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

7.  Mutator phenotypes in human colorectal carcinoma cell lines.

Authors:  N P Bhattacharyya; A Skandalis; A Ganesh; J Groden; M Meuth
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

8.  Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage.

Authors:  M Nyström-Lahti; R Parsons; P Sistonen; L Pylkkänen; L A Aaltonen; F S Leach; S R Hamilton; P Watson; E Bronson; R Fusaro
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

9.  Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer.

Authors:  J R Eshleman; E Z Lang; G K Bowerfind; R Parsons; B Vogelstein; J K Willson; M L Veigl; W D Sedwick; S D Markowitz
Journal:  Oncogene       Date:  1995-01-05       Impact factor: 9.867

10.  Hypermutability and mismatch repair deficiency in RER+ tumor cells.

Authors:  R Parsons; G M Li; M J Longley; W H Fang; N Papadopoulos; J Jen; A de la Chapelle; K W Kinzler; B Vogelstein; P Modrich
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

View more
  16 in total

1.  Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Authors:  Zishuo I Hu; Jinru Shia; Zsofia K Stadler; Anna M Varghese; Marinela Capanu; Erin Salo-Mullen; Maeve A Lowery; Luis A Diaz; Diana Mandelker; Kenneth H Yu; Alice Zervoudakis; David P Kelsen; Christine A Iacobuzio-Donahue; David S Klimstra; Leonard B Saltz; Ibrahim H Sahin; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2018-01-24       Impact factor: 12.531

2.  Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics.

Authors:  Sven Arnold; Daniel D Buchanan; Melissa Barker; Lesley Jaskowski; Michael D Walsh; Genevieve Birney; Michael O Woods; John L Hopper; Mark A Jenkins; Melissa A Brown; Sean V Tavtigian; David E Goldgar; Joanne P Young; Amanda B Spurdle
Journal:  Hum Mutat       Date:  2009-05       Impact factor: 4.878

3.  Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.

Authors:  Yaacov R Lawrence; Jennifer Moughan; Anthony M Magliocco; Alexander C Klimowicz; William F Regine; Rex B Mowat; Thomas A DiPetrillo; William Small; Jeffry P Simko; Talia Golan; Kathryn A Winter; Chandan Guha; Christopher H Crane; Adam P Dicker
Journal:  Cancer       Date:  2017-10-20       Impact factor: 6.860

4.  Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors.

Authors:  Christian N Arnold; Takeshi Nagasaka; Ajay Goel; Iris Scharf; Patricia Grabowski; Andrea Sosnowski; Annette Schmitt-Gräff; C Richard Boland; Rudolf Arnold; Hubert E Blum
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

Review 5.  Current approaches to novel therapeutics in pancreatic cancer.

Authors:  Corina E Akerele; Irina Rybalova; Howard L Kaufman; Sridhar Mani
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

Review 6.  Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.

Authors:  Georg Feldmann; Anirban Maitra
Journal:  J Mol Diagn       Date:  2008-02-07       Impact factor: 5.568

7.  Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.

Authors:  Luigi Laghi; Stefania Beghelli; Antonino Spinelli; Paolo Bianchi; Gianluca Basso; Giuseppe Di Caro; Anna Brecht; Giuseppe Celesti; Giona Turri; Samantha Bersani; Guido Schumacher; Christoph Röcken; Ilona Gräntzdörffer; Massimo Roncalli; Alessandro Zerbi; Peter Neuhaus; Claudio Bassi; Marco Montorsi; Aldo Scarpa; Alberto Malesci
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

8.  Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only.

Authors:  Niki A Ottenhof; Folkert H M Morsink; Fiebo Ten Kate; Cornelis J F van Noorden; G Johan A Offerhaus
Journal:  Cell Oncol (Dordr)       Date:  2012-02-18       Impact factor: 6.730

Review 9.  Genetic alterations in pancreatic carcinoma.

Authors:  Gunter Schneider; Roland M Schmid
Journal:  Mol Cancer       Date:  2003-01-22       Impact factor: 27.401

10.  Prevalence of pathological germline mutations of hMLH1 and hMSH2 genes in colorectal cancer.

Authors:  Dandan Li; Fulan Hu; Fan Wang; Binbin Cui; Xinshu Dong; Wencui Zhang; Chunqing Lin; Xia Li; Da Wang; Yashuang Zhao
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.